Introduction Cardiovascular disease (CVD) prevention is practiced concurrently by providers
from several specialties. Our goal was to understand providers' preference of specialties in …

Objectives. The aim of this study was to examine physician specialty differences in
cardiovascular disease prevention practices. Background. Despite the importance of …

The rapidly expanding field of preventive cardiology has brought with it several major
advances in the past decade. Changes in guidelines for cholesterol mangement focusing on …

Background SGLT2 inhibitors (SGLT2i) have been shown to reduce cardiovascular risk and
heart failure hospitalizations in patients with cardiovascular disease with or without T2DM …

Background: Prior studies found patients treated with sodium-glucose co-transporter-2
inhibitors (SGLT-2i) had lower rates of death and heart failure (HF). Whether the benefits of …

As a continuing medical education provider accredited by the Accreditation Council for
Continuing Medical Education (ACCME), Primary Care Education Consortium (PCEC) …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to
reduce cardiovascular risk in patients with T2DM and CVD, yet the cardiology community at …

Background Public health prevention strategies have been developed to overcome the
disease burden. Despite all the available resources, there have been several challenges in …

BACKGROUND: Quality of cardiovascular disease (CVD) preventive care is suboptimal.
Recent data correlated increasing years in practice for physicians with lower-quality health …

Objective To determine the real-world use of pharmacotherapy with new evidence-based
cardiovascular indications in an academic Preventive Cardiology Clinic. Methods A …